JPWO2022140665A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022140665A5 JPWO2022140665A5 JP2023538969A JP2023538969A JPWO2022140665A5 JP WO2022140665 A5 JPWO2022140665 A5 JP WO2022140665A5 JP 2023538969 A JP2023538969 A JP 2023538969A JP 2023538969 A JP2023538969 A JP 2023538969A JP WO2022140665 A5 JPWO2022140665 A5 JP WO2022140665A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- item
- tcr
- acid molecule
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008874 T cell receptors Proteins 0.000 claims description 226
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 226
- 150000007523 nucleic acids Chemical group 0.000 claims description 216
- 210000004027 cell Anatomy 0.000 claims description 191
- 108020004707 nucleic acids Proteins 0.000 claims description 136
- 102000039446 nucleic acids Human genes 0.000 claims description 136
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 80
- 102000003812 Interleukin-15 Human genes 0.000 claims description 66
- 108090000172 Interleukin-15 Proteins 0.000 claims description 66
- 239000012634 fragment Substances 0.000 claims description 63
- 229920001184 polypeptide Polymers 0.000 claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 63
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 63
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 238000003776 cleavage reaction Methods 0.000 claims description 13
- 230000007017 scission Effects 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 8
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 8
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 8
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 8
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 102100032530 Glypican-3 Human genes 0.000 claims description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000011748 cell maturation Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 description 52
- 238000000034 method Methods 0.000 description 29
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000000139 costimulatory effect Effects 0.000 description 8
- -1 ICOS (CD278) Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 5
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 102000003735 Mesothelin Human genes 0.000 description 4
- 108090000015 Mesothelin Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 229940126530 T cell activator Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100035486 Nectin-4 Human genes 0.000 description 1
- 101710043865 Nectin-4 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- TUGMVGKTLNQWJN-UHFFFAOYSA-N morpholin-4-ylmethylphosphonic acid Chemical class OP(O)(=O)CN1CCOCC1 TUGMVGKTLNQWJN-UHFFFAOYSA-N 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129829P | 2020-12-23 | 2020-12-23 | |
| US63/129,829 | 2020-12-23 | ||
| US202163225821P | 2021-07-26 | 2021-07-26 | |
| US63/225,821 | 2021-07-26 | ||
| US202163250329P | 2021-09-30 | 2021-09-30 | |
| US63/250,329 | 2021-09-30 | ||
| US202163257345P | 2021-10-19 | 2021-10-19 | |
| US63/257,345 | 2021-10-19 | ||
| PCT/US2021/065069 WO2022140665A1 (en) | 2020-12-23 | 2021-12-23 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501831A JP2024501831A (ja) | 2024-01-16 |
| JP2024501831A5 JP2024501831A5 (https=) | 2024-12-04 |
| JPWO2022140665A5 true JPWO2022140665A5 (https=) | 2024-12-04 |
Family
ID=82160130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538969A Pending JP2024501831A (ja) | 2020-12-23 | 2021-12-23 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240117002A1 (https=) |
| EP (1) | EP4267733A4 (https=) |
| JP (1) | JP2024501831A (https=) |
| AU (1) | AU2021410788A1 (https=) |
| CA (1) | CA3203180A1 (https=) |
| WO (1) | WO2022140665A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240252641A1 (en) * | 2020-05-05 | 2024-08-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| AU2023338694A1 (en) * | 2022-09-08 | 2025-04-03 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA3036745A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| US11851491B2 (en) * | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3638295A1 (en) * | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20210015859A1 (en) * | 2017-12-08 | 2021-01-21 | Fate Therapeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CA3093449A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| WO2020198033A1 (en) * | 2019-03-22 | 2020-10-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20230069322A1 (en) * | 2019-12-24 | 2023-03-02 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| US20240252641A1 (en) * | 2020-05-05 | 2024-08-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
-
2021
- 2021-12-23 CA CA3203180A patent/CA3203180A1/en active Pending
- 2021-12-23 EP EP21912227.2A patent/EP4267733A4/en active Pending
- 2021-12-23 JP JP2023538969A patent/JP2024501831A/ja active Pending
- 2021-12-23 US US18/269,214 patent/US20240117002A1/en active Pending
- 2021-12-23 AU AU2021410788A patent/AU2021410788A1/en not_active Abandoned
- 2021-12-23 WO PCT/US2021/065069 patent/WO2022140665A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404492B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP2022050420A (ja) | キメラ抗原受容体発現細胞の製造法 | |
| WO2018059549A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| JP2021515598A5 (https=) | ||
| CA3206549A1 (en) | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| JP2018515123A5 (https=) | ||
| JP2017522879A5 (https=) | ||
| EP4055049A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| EP4121518A1 (en) | Engineered cell compositions and methods of use thereof | |
| US20220185882A1 (en) | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same | |
| JPWO2021173995A5 (https=) | ||
| JPWO2019173693A5 (https=) | ||
| JPWO2022140665A5 (https=) | ||
| US20220370498A1 (en) | Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla gene | |
| JP7631234B2 (ja) | Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞 | |
| JPWO2021050948A5 (https=) | ||
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP2025525453A (ja) | 悪性ｂ細胞疾患の処置において使用するためのキメラチェックポイント受容体 | |
| CN118048312A (zh) | 靶向cd19和/或cd20的car-nk细胞及其制备与应用 | |
| CN116964082A (zh) | Fc受体CAR构建体和细胞 | |
| HK1248273B (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| HK1248273A1 (en) | Methods for enhancing efficacy of therapeutic immune cells |